Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 7,136 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 7,136 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

William Richard White also recently made the following trade(s):

• On Friday, November 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $46.37, for a total transaction of $9,320.37.
• On Tuesday, October 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $51.31, for a total value of $10,313.31.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $64.78 on Wednesday. The firm’s 50 day moving average price is $48.75 and its 200-day moving average price is $42.93. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The company has a market cap of $1.93 billion, a PE ratio of -17.65 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.08. On average, analysts forecast that Disc Medicine, Inc. will post -4.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Disc Medicine in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $75.00 target price (up from $60.00) on shares of Disc Medicine in a research report on Monday. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target for the company. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $66.00 to $110.00 in a report on Monday. Finally, Jefferies Financial Group began coverage on shares of Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price for the company. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $80.20.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its stake in Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock valued at $79,090,000 after acquiring an additional 969,834 shares during the period. Logos Global Management LP purchased a new position in shares of Disc Medicine during the second quarter valued at approximately $41,690,000. Point72 Asset Management L.P. bought a new position in Disc Medicine during the second quarter valued at approximately $34,318,000. Deerfield Management Company L.P. Series C boosted its holdings in Disc Medicine by 53.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after purchasing an additional 357,730 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Disc Medicine by 59.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after purchasing an additional 353,382 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.